Keywords: expenses, increase, topotarget, loss, danish, drugmaker, says
R&D expenses increase TopoTarget's loss 26%
Article | 19 November 2007
Danish drugmaker TopoTarget says that, for the nine months ended September 30, 2007, its loss was 155.3 million Danish kroner ($30.3 million), a 26.5% increase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
